Christian Anker-Ladefoged

Jump-start your R&D with an affordable, versatile and easy-to-use microscope. Nebula can simultaneously image bright-field, phase contrast and 3D thickness maps, with full automation, and without any external PCs or displays. And its much more affordable than you might think. Just check our website to receive an online quote within minutes, or to book a demonstration. Life science has never been this accessible.

At VentriJect, we want to change how we work with cardiorespiratory fitness. Cardiorespiratory fitness, also expressed as VO2max, is the strongest indicator of health, according to several studies, and even small improvements in VO2max can mean a significant health improvement. Unfortunately, evaluating cardiorespiratory fitness today can be cumbersome, time-consuming, expensive and dependent on highly-trained staff. At VentriJect we want to change that. Introducing the Seismofit - a radical new approach to evaluating cardiorespiratory fitness. With high accuracy, no training required, and extreme ease of use, we can estimate your VO2max in less than 3 minutes - a fraction of the time used with other approaches. This clinical-validated and patented technology is unique and a true game-changer, and will provide significant value to the patients and the healthcare practitioners. VentriJect was established as a spin-out from a leading research center in cardiology at Aalborg University in 2018 and is situated in Hellerup near Copenhagen, Denmark.

Our vision is to enable rapid and local tests for anticoagulants at the point-of-care to benefit patients. Currently, there is no readily available solutions to address blood levels of anticoagulants called Direct Oral Anticoagulants (DOACs) at the point-of-care. We have developed a novel technology, chip and instrument that can detect anticoagulants, directly from whole blood within only 10 minutes. The elegant simplicity of our solution will potentially be readily available at the point of care.

Pephexia Therapeutics is a biotechnology company working with the discovery and development of innovative peptide-based pharmacotherapies for an effective and convenient treatment of cachexia and related diseases.

Antag Therapeutics is a biotechnology company pioneering personal and flexible obesity treatment through GIP receptor antagonism. Antag’s lead molecule AT-7687 is specifically designed to target and deactivate the GIP receptor, a genetically-validated pathway that contributes to fat storage, insulin resistance, and metabolic dysfunction – and is mechanistically distinct from GLP-1 therapies. Antag’s GIPR antagonist approach stems from the work of the esteemed research teams of Professors Jens Juul Holst and Mette Rosenkilde, two co-founders of the business. Antag’s vision is that all people living with obesity, diabetes and overweight have a personal treatment option that goes beyond weight loss to improve long-term health, without having to compromise on tolerability.

Digital, AI based patient monitor software to enable continuous monitoring of patients in the hospital and at home

At GLX ANALYTIX, we combine proprietary biomarkers with machine learning to bring personalized medicine to your healthcare. We are currently growing our team. Feel free to get in touch!

Innovations that make a difference Ever since 1937, Ambu has been rethinking medical solutions to save lives and improve patient care. Millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. In the past, we provided a way to maintain or restore breathing in any environment with the world’s first self-inflating resuscitator, the Ambu® Bag™, which is still in use today. More recently, we responded to a need for an endoscopy solution that is always available. The result? Ambu® aScope™, the world’s first sterile, single-use flexible endoscope. Today, we continue to collaborate with leading medical experts to deliver innovations that make a real difference to healthcare professionals and their patients. At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America and the Asia Pacific, 5,000+ team members keep Ambu moving forward. For more information, please visit www.ambu.com

Jump-start your R&D with an affordable, versatile and easy-to-use microscope. Nebula can simultaneously image bright-field, phase contrast and 3D thickness maps, with full automation, and without any external PCs or displays. And its much more affordable than you might think. Just check our website to receive an online quote within minutes, or to book a demonstration. Life science has never been this accessible.

At VentriJect, we want to change how we work with cardiorespiratory fitness. Cardiorespiratory fitness, also expressed as VO2max, is the strongest indicator of health, according to several studies, and even small improvements in VO2max can mean a significant health improvement. Unfortunately, evaluating cardiorespiratory fitness today can be cumbersome, time-consuming, expensive and dependent on highly-trained staff. At VentriJect we want to change that. Introducing the Seismofit - a radical new approach to evaluating cardiorespiratory fitness. With high accuracy, no training required, and extreme ease of use, we can estimate your VO2max in less than 3 minutes - a fraction of the time used with other approaches. This clinical-validated and patented technology is unique and a true game-changer, and will provide significant value to the patients and the healthcare practitioners. VentriJect was established as a spin-out from a leading research center in cardiology at Aalborg University in 2018 and is situated in Hellerup near Copenhagen, Denmark.

Our vision is to enable rapid and local tests for anticoagulants at the point-of-care to benefit patients. Currently, there is no readily available solutions to address blood levels of anticoagulants called Direct Oral Anticoagulants (DOACs) at the point-of-care. We have developed a novel technology, chip and instrument that can detect anticoagulants, directly from whole blood within only 10 minutes. The elegant simplicity of our solution will potentially be readily available at the point of care.

Pephexia Therapeutics is a biotechnology company working with the discovery and development of innovative peptide-based pharmacotherapies for an effective and convenient treatment of cachexia and related diseases.